The strawberry-derived flavonoid that outperformed quercetin, extended lifespan in aged mice, and is now at the center of anti-aging research
Fisetin is a flavonoid polyphenol found naturally in strawberries, apples, persimmons, and several other fruits and vegetables. For decades it was studied primarily as an antioxidant and anti-inflammatory compound. Then a landmark 2018 paper changed everything.
Researchers at the Mayo Clinic and the University of Minnesota screened ten natural compounds for their ability to clear senescent cells — the so-called "zombie cells" that accumulate in aging tissue, resist normal cell death, and actively damage surrounding healthy cells. Fisetin came out on top, demonstrating potency far exceeding quercetin, curcumin, and other well-studied polyphenols.
The finding ignited a wave of interest in fisetin as a practical, accessible senolytic: a compound capable of selectively eliminating senescent cells and — at least in animal models — extending both healthspan and lifespan. This guide walks through the biology, the evidence, and what a realistic dosing protocol looks like based on current research.
Senolytics matter because aging is not simply the passage of time — it is, in large part, the accumulation of biological damage. Senescent cells sit at the center of that damage cascade. Clearing them is one of the most mechanistically coherent strategies in the entire longevity field, and fisetin has emerged as the most promising natural tool available for doing so.
When a cell sustains damage — from DNA breaks, oxidative stress, telomere shortening, or oncogenic signals — it faces a choice: repair itself, undergo apoptosis (programmed death), or enter a state of permanent cell-cycle arrest called senescence. Senescence evolved as a protective mechanism, preventing damaged cells from becoming cancerous. In young, healthy organisms, the immune system efficiently identifies and clears senescent cells before they cause problems.
The problem is that clearance becomes less efficient with age. Senescent cells accumulate in fat tissue, joints, the liver, lungs, vasculature, and brain. And crucially, these cells do not simply sit dormant. They secrete a toxic cocktail of inflammatory signals known as the senescence-associated secretory phenotype, or SASP.
SASP cytokines include IL-6, IL-8, and TNF-alpha — the same signals found elevated in nearly every major age-related disease: cardiovascular disease, type 2 diabetes, neurodegeneration, and cancer. This chronic low-grade inflammation driven by accumulating senescent cells is increasingly called "inflammaging" — and it may be the single most important driver of the aging phenotype.
Senescent cells also spread their dysfunction to neighboring cells through paracrine signaling, converting healthy tissue into a senescent microenvironment. In animal models, transplanting even small numbers of senescent cells into young mice causes measurable physical decline within weeks. Conversely, clearing senescent cells — genetically or pharmacologically — restores function, reduces disease burden, and extends lifespan.
This is the target fisetin is aiming at. Rather than merely neutralizing the SASP with anti-inflammatories, senolytics go further: they eliminate the senescent cells themselves, removing the source of the problem rather than managing its downstream effects.
This Mayo Clinic-led study systematically screened ten natural compounds for senolytic activity. Fisetin was the clear winner, outperforming quercetin, curcumin, luteolin, and six others. In aged mice, fisetin administration reduced the burden of senescent cells by approximately 50%, as measured by p21, p16, and SASP marker expression across multiple tissues. The treated mice also lived measurably longer — median lifespan extended by roughly 10% even when treatment began late in life. Critically, the researchers found fisetin effective in both cell culture and in vivo models, lending confidence to the translation.
↑ 10% median lifespan extension in aged miceDr. James Kirkland's group at Mayo Clinic has been the most influential voice establishing the causal role of senescent cells in age-related dysfunction. Their work demonstrated that clearing just 30% of senescent cells in aged mice was sufficient to restore physical function, reduce frailty, and extend healthspan. This established an important principle: you don't need to eliminate all senescent cells — even partial clearance provides disproportionate benefit. Kirkland's group also pioneered the dasatinib + quercetin (D+Q) combination, which has since advanced into human clinical trials for conditions including diabetic kidney disease, Alzheimer's disease, and COVID-19 complications.
30% senescent cell clearance → measurable healthspan restorationFisetin shows particular promise in the brain. Unlike many polyphenols, fisetin readily crosses the blood-brain barrier, enabling direct action on neuronal senescence. Studies in Alzheimer's mouse models show fisetin reduces amyloid beta accumulation, neuroinflammation, and cognitive decline. The mechanisms include inhibition of mTOR (a key aging pathway), activation of SIRT1 (a longevity-associated deacetylase), and direct suppression of neuroinflammatory SASP factors. This dual action — senolytic clearance plus direct neuroprotection — makes fisetin particularly interesting as a cognitive aging intervention.
Crosses BBB; activates SIRT1; inhibits mTOR signalingUnity Biotechnology launched the first human senolytic clinical trials using navitoclax (a synthetic BCL-2 inhibitor), targeting the same apoptotic pathway that fisetin engages through natural means. Their trials in osteoarthritis patients demonstrated that intra-articular senolytic treatment reduced pain and improved function, validating the senolytic hypothesis in humans for the first time. While navitoclax has dose-limiting toxicity (thrombocytopenia), fisetin targets BCL-2 family proteins with considerably lower off-target effects — one reason it remains the leading natural senolytic candidate. Multiple Phase 1/2 trials with fisetin are currently registered at ClinicalTrials.gov.
First human validation of senolytic hypothesis in osteoarthritisSenescent cells resist apoptosis — that's part of what makes them accumulate. They upregulate BCL-2 family proteins (BCL-2, BCL-XL, BCL-W) which act as survival signals, essentially bribing the apoptosis machinery into staying dormant. Senolytics work by neutralizing these survival signals, allowing the apoptotic program to proceed in senescent cells while leaving healthy cells unharmed.
Fisetin targets this pathway directly. It inhibits BCL-2 and BCL-XL activity, effectively disabling the survival shield that senescent cells depend on. Because normal, healthy cells have lower dependence on BCL-2 survival signaling, fisetin achieves a degree of selectivity — it preferentially eliminates cells that have become senescent while leaving non-senescent cells intact.
Beyond its senolytic mechanism, fisetin also operates through several complementary pathways that make it particularly compelling for longevity applications:
This multi-target profile distinguishes fisetin from synthetic senolytics that typically have a single, highly specific mechanism. Whether this breadth is an advantage or a limitation in terms of dosing precision remains an open question, but it may explain why fisetin's safety profile appears favorable even at doses well above typical dietary intake.
Fisetin occurs naturally in a range of fruits and vegetables, though concentrations are too low to achieve senolytic dosing through diet alone. Strawberries contain by far the highest concentration — roughly 160 micrograms per gram of fresh weight — making them the most practical dietary source.
To achieve the 500–1000mg dose used in mouse studies (scaled to human equivalents), you would need to consume approximately 3–6 kilograms of strawberries in a single day — clearly impractical as a regular intervention. This is why supplementation is considered necessary for anyone using fisetin as a deliberate senolytic protocol rather than a general dietary health practice.
That said, regular dietary intake of fisetin-rich foods — particularly strawberries — likely provides meaningful background benefit over years and decades: lower baseline senescent cell burden, ongoing antioxidant and anti-inflammatory activity, and support for the broader flavonoid ecosystem that enables good metabolic health.
The dosing approach for fisetin as a senolytic differs fundamentally from taking a daily supplement. Senolytics are not meant to be taken every day — they are most effective (and safest) when used in short, high-dose "pulse" cycles designed to clear accumulated senescent cells, followed by a recovery period during which the body clears cellular debris and regenerates healthy cells.
Important caveat: All human dosing protocols for fisetin as a senolytic are extrapolated from mouse studies and early-phase clinical data. There are no completed Phase 3 human trials establishing optimal dose, frequency, or long-term safety for senolytic use. The protocols above reflect current best-practice inference from available evidence, not established clinical guidelines.
How does fisetin stack up against the other major senolytics — both natural and pharmaceutical?
| Compound | Type | Senolytic Potency | Human Evidence | Accessibility |
|---|---|---|---|---|
| Fisetin | Natural flavonoid | Highest (natural) | Phase 1/2 trials ongoing | OTC supplement |
| Quercetin | Natural flavonoid | Moderate | D+Q Phase 2 trials completed | OTC supplement |
| Dasatinib | BCR-ABL inhibitor (Rx) | High (synergistic) | Phase 2 completed (DKD, IPF) | Prescription only |
| Navitoclax | BCL-2/XL inhibitor (Rx) | Very high | Phase 1/2 (OA, MF) | Clinical trials only |
| Curcumin | Natural polyphenol | Weak | Minimal senolytic data | OTC supplement |
| Piperlongumine | Alkaloid | Moderate | Preclinical only | Limited availability |
DKD = diabetic kidney disease; IPF = idiopathic pulmonary fibrosis; OA = osteoarthritis; MF = myelofibrosis. Potency comparisons based on Yousefzadeh et al. 2018 and subsequent review literature.
Fisetin is the most compelling accessible senolytic available without a prescription. The 2018 Yousefzadeh study is robust, the mechanism is well-understood, and the safety profile — based on decades of flavonoid research and growing clinical experience — appears favorable. The major caveat is the gap between mouse-study results and human clinical confirmation, which remains open pending completion of ongoing trials.
Primary limitation: human senolytic efficacy at affordable doses is not yet confirmed. The optimal human dose, cycle frequency, and long-term safety remain open questions. Those with significant health conditions, or taking medications that interact with BCL-2 pathway modulation, should consult a physician before beginning a fisetin protocol.
As an Amazon Associate, LongevityLab earns from qualifying purchases. Prices and availability may vary.
Standard senolytic dose. Look for products with standardized extract (≥98% purity) and fat-soluble formulations for improved bioavailability.
Compare brands, dosages, and formulations. Prioritize third-party tested products with certificates of analysis.
Combined senolytic supplements. The natural approximation of the D+Q protocol — synergistic BCL-2 inhibition from two complementary flavonoids.
Buying Tip: When evaluating fisetin supplements, look for: (1) standardized extract with stated purity percentage, (2) phospholipid complex or liposomal formulation for better absorption, (3) third-party testing (NSF, Informed Sport, or USP), and (4) transparent supplier information. Avoid products that blend fisetin into "proprietary complexes" where individual doses are undisclosed.